Single User License
INR 133660
Site License
INR 267320
Corporate User License
INR 400980

Service Tax Additional

select a format

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Severe Psoriasis-Pipeline Review, H1 2015

Severe Psoriasis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6610IDB
  • |
  • Pages: 110
  • |
  • April 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Severe Psoriasis-Pipeline Review, H1 2015


Global Markets Direct's, 'Severe Psoriasis-Pipeline Review, H1 2015', provides an overview of the Severe Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Severe Psoriasis Overview 8

Therapeutics Development 9

Pipeline Products for Severe Psoriasis-Overview 9

Pipeline Products for Severe Psoriasis-Comparative Analysis 10

Severe Psoriasis-Therapeutics under Development by Companies 11

Severe Psoriasis-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Severe Psoriasis-Products under Development by Companies 14

Severe Psoriasis-Companies Involved in Therapeutics Development 16

Almirall, S.A. 16

Amgen Inc. 17

ApoPharma Inc. 18

Boehringer Ingelheim GmbH 19

Covagen AG 20

Eli Lilly and Company 21

Idera Pharmaceuticals, Inc. 22

Johnson & Johnson 23

Merck KGaA 24

Pfizer Inc. 25

Sandoz International GmbH 26

Sun Pharmaceutical Industries Inc. 27

Syntrix Biosystems, Inc. 28

UCB S.A. 29

Valeant Pharmaceuticals International, Inc. 30

XenoPort, Inc. 31

Severe Psoriasis-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

adalimumab biosimilar-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

adalimumab biosimilar-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

aminopterin sodium-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

baricitinib-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BI-655066-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

brodalumab-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

certolizumab pegol-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

COVA-322-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

dimethyl fumarate-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

etanercept biosimilar-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

guselkumab-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

IDP-118-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

IMO-8400-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ixekizumab-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

MSB-0010841-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

orilotimod potassium-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

PF-04965842-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

tildrakizumab-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

toreforant-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

ustekinumab-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

XP-23829-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Severe Psoriasis-Recent Pipeline Updates 77

Severe Psoriasis-Dormant Projects 105

Severe Psoriasis-Discontinued Products 106

Severe Psoriasis-Product Development Milestones 107

Featured News & Press Releases 107

Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 107

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Tables

Number of Products under Development for Severe Psoriasis, H1 2015 9

Number of Products under Development for Severe Psoriasis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Development by Companies, H1 2015 (Contd..1) 15

Severe Psoriasis-Pipeline by Almirall, S.A., H1 2015 16

Severe Psoriasis-Pipeline by Amgen Inc., H1 2015 17

Severe Psoriasis-Pipeline by ApoPharma Inc., H1 2015 18

Severe Psoriasis-Pipeline by Boehringer Ingelheim GmbH, H1 2015 19

Severe Psoriasis-Pipeline by Covagen AG, H1 2015 20

Severe Psoriasis-Pipeline by Eli Lilly and Company, H1 2015 21

Severe Psoriasis-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 22

Severe Psoriasis-Pipeline by Johnson & Johnson, H1 2015 23

Severe Psoriasis-Pipeline by Merck KGaA, H1 2015 24

Severe Psoriasis-Pipeline by Pfizer Inc., H1 2015 25

Severe Psoriasis-Pipeline by Sandoz International GmbH, H1 2015 26

Severe Psoriasis-Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 27

Severe Psoriasis-Pipeline by Syntrix Biosystems, Inc., H1 2015 28

Severe Psoriasis-Pipeline by UCB S.A., H1 2015 29

Severe Psoriasis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 30

Severe Psoriasis-Pipeline by XenoPort, Inc., H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

Severe Psoriasis Therapeutics-Recent Pipeline Updates, H1 2015 77

Severe Psoriasis-Dormant Projects, H1 2015 105

Severe Psoriasis-Discontinued Products, H1 2015 106

List of Figures

Number of Products under Development for Severe Psoriasis, H1 2015 9

Number of Products under Development for Severe Psoriasis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 33

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Almirall, S.A.

Amgen Inc.

ApoPharma Inc.

Boehringer Ingelheim GmbH

Covagen AG

Eli Lilly and Company

Idera Pharmaceuticals, Inc.

Johnson & Johnson

Merck KGaA

Pfizer Inc.

Sandoz International GmbH

Sun Pharmaceutical Industries Inc.

Syntrix Biosystems, Inc.


Valeant Pharmaceuticals International, Inc.

XenoPort, Inc.

Severe Psoriasis Therapeutic Products under Development, Key Players in Severe Psoriasis Therapeutics, Severe Psoriasis Pipeline Overview, Severe Psoriasis Pipeline, Severe Psoriasis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]